Document is current
Any future updates will be listed below
-
Authors
Muchtar, Eli https://orcid.org/0000-0003-2210-2174
Dispenzieri, Angela https://orcid.org/0000-0001-8780-9512
Sanchorawala, Vaishali https://orcid.org/0000-0002-6307-2445
Hassan, Hamza https://orcid.org/0000-0003-1775-2703
Mwangi, Raphael
Maurer, Matthew https://orcid.org/0000-0002-1867-0526
Buadi, Francis https://orcid.org/0000-0003-3214-0203
Lee, Hans C. https://orcid.org/0000-0001-8545-3292
Qazilbash, Muzaffar https://orcid.org/0000-0003-2876-2886
Kin, Andrew https://orcid.org/0000-0002-3263-2374
Zonder, Jeffrey
Arai, Sally https://orcid.org/0000-0003-1993-4172
Chin, Michelle M.
Chakraborty, Rajshekhar https://orcid.org/0000-0001-7336-3003
Lentzsch, Suzanne
Magen, Hila https://orcid.org/0000-0002-3990-394X
Shkury, Eden
Sarubbi, Caitlin
Landau, Heather https://orcid.org/0000-0002-3152-1189
Schönland, Stefan https://orcid.org/0000-0002-4853-5579
Hegenbart, Ute https://orcid.org/0000-0003-1917-6746
Gertz, Morie https://orcid.org/0000-0002-3853-5196
-
Funding
Funding for this research was provided by:
Dr. Muchtar was supported by the Mayo Clinic Transplant Center Scholarly Award.
- License Information
-
More Information
Article History
Received: 19 November 2024
Revised: 31 January 2025
Accepted: 14 February 2025
First Online: 24 February 2025
Competing interests
: EM received a consultation fee from Protego (a fee paid to the institution). AD received research funding from Celgene, Millennium Pharmaceuticals, Pfizer, and Janssen and received a travel grant from Pfizer. VS received research support from Celgene, Millennium-Takeda, Janssen, Prothena, Sorrento, Karyopharm, Oncopeptide, Caelum, serves as a consultant for Janssen and Pfizer and served on the advisory board for Proclara, Caelum, Abbvie, Janssen, Regeneron, Protego, Pharmatrace, Telix, Prothena. MM received research funding from Roche/Genentech, BMS, and GenMab and provided consultancy/Advisory Board for AstraZeneca and BMS. HCL received research funding from Amgen, Bristol Myers Squibb, Janssen, GlaxoSmithKline, Regeneron, and Takeda Pharmaceuticals and provided consultancy to Abbvie, Bristol Myers Squibb, Janssen, Regeneron, GlaxoSmithKline, Sanofi, Takeda Pharmaceuticals, Allogene Therapeutics, and Pfizer. RC serves as Consultant/Advisory Board for Janssen, Sanofi, Adaptive Biotech and received research funding from Genentech, AbbVie. UH received honoraria from Janssen, Pfizer, Alnylam, Prothena, Astra Zeneca, received financial support for congress participation from Janssen, Prothena, and Pfizer, serves on advisory Boards for Pfizer, Prothena, Janssen, Alexion, Alnylam and received financial sponsoring of Amyloidosis Registry from Janssen. MAG served as a consultant for Millennium Pharmaceuticals and received honoraria from Celgene, Millennium Pharmaceuticals, Onyx Pharmaceuticals, Novartis, GlaxoSmithKline, Prothena, Ionis Pharmaceuticals, and Amgen). The remaining authors declare no competing financial interests.
: All methods were performed in accordance with the relevant guidelines and regulations. The study was approved by the IRBs in all participating centers [lead site (Mayo Clinic) IRB number 20-011936]. Informed consent for medical research was obtained from all participants.
